Acticor Biotech Provides an Update on the Current Receivership Proceedings
ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today provides an update on the current receivership...

